ICS/福莫特罗维持缓解治疗在重症哮喘中的证据基础
该文回应UKSAR数据与RCT人群严重度差异的讨论,指出ICS/福莫特罗MART是重症哮喘高危患者基于证据的替代方案。RCT与重症哮喘登记库之间的人群差异同样适用于高剂量ICS/LABA加SABA方案,MART研究和高剂量ICS/LABA研究均存在相似的平均基线严重度差异。
要点
- ICS/福莫特罗MART是重症哮喘高危患者基于证据的替代方案
- RCT与UKSAR人群严重度差异同样见于高剂量ICS/LABA研究
- MART与高剂量ICS/LABA研究的基线严重度差异相似
核心结论
- ICS/福莫特罗MART是重症哮喘高危患者基于证据的替代方案。
- RCT外推至重症哮喘登记库的局限性同样适用于高剂量ICS/LABA加SABA方案。
主要发现
- UKSAR记录的患者平均哮喘严重度高于ICS/福莫特罗MART的RCT参与者。
- UKSAR与高剂量ICS/LABA加SABA的RCT参与者之间也存在相似的基线严重度差异。
- MART研究与高剂量ICS/LABA研究的平均基线严重度差异相似。
临床怎么用
- 对重症哮喘且严重急性发作高风险患者,可考虑ICS/福莫特罗MART作为高剂量ICS/LABA的替代方案。
局限性
- RCT与重症哮喘登记库人群的平均基线严重度存在差异,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ICS/formoterol MART is an evidence-based alternative to high dose ICS/LABA in asthma patients at high risk of severe exacerbations; limited generalisability of RCTs to severe asthma registries applies similarly to high dose ICS/LABA therapy as to MART https://bit.ly/4aVFrNH We agree with P.J. McDowell and co-workers that the patients whose data are recorded in the UK Severe Asthma Registry (UKSAR) have, on average, more severe asthma than participants in randomised controlled trials (RCTs) of inhaled corticosteroid (ICS)/formoterol maintenance and reliever therapy (MART) [1, 2]. However, poor generalisability from RCTs to severe asthma registries is also the case for RCTs of high dose ICS/long-acting β-agonist (LABA) plus short-acting β-agonist (SABA) reliever therapy. There are similar differences in average baseline severity between patients in the UKSAR database and participants in RCTs of high dose versus medium dose ICS/LABA plus SABA therapy, as with those in the MART studies (table 1) [3–13].
引用
- Beasley R, Noble J, Weatherall M, et al. The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma. Eur Respir J. 2024. PMID: 38901890. doi:10.1183/13993003.00523-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。